急性心肌梗死后左心室游离壁破裂保守治疗存活一例
左心室游离壁破裂(LVFWR)是急性心肌梗死(AMI)后罕见且致命的机械并发症,STEMI后LVFWR经保守治疗策略存活者极为罕见。本例为55岁男性,有多种心血管危险因素,因持续胸痛和晕厥就诊急诊科,心电图示窦性心律,I、aVL、V4-6导联ST段抬高,肌红蛋白和肌钙蛋白I升高。因血流动力学不稳定行床旁超声心动图,提示AMI后LVFWR,予心包穿刺恢复满意血流动力学状态。初始治疗后患者选择保守治疗策略,19天后平安出院。
要点
- 55岁男性STEMI患者因持续胸痛和晕厥就诊,心电图示I、aVL、V4-6导联ST段抬高,肌红蛋白和肌钙蛋白I升高。
- 因血流动力学不稳定行床旁超声心动图,提示AMI后左心室游离壁破裂(LVFWR)。
- 予心包穿刺恢复满意血流动力学状态,此后患者选择保守治疗策略。
- 保守治疗后患者19天平安出院,为STEMI后LVFWR保守治疗存活病例。
适用人群与场景
- 55岁男性,有多种心血管危险因素,因持续胸痛和晕厥就诊急诊科,心电图示窦性心律伴I、aVL、V4-6导联ST段抬高,肌红蛋白和肌钙蛋白I升高,因血流动力学不稳定行床旁超声心动图。
处置流程与药物剂量
- 因血流动力学不稳定行床旁超声心动图,提示AMI后LVFWR。
- 予心包穿刺以恢复满意血流动力学状态。
- 初始治疗后患者选择保守治疗策略,19天后平安出院。
研究设计与关键结果
- 病例报告:55岁男性STEMI后发生LVFWR,因血流动力学不稳定行床旁超声确诊,心包穿刺恢复满意血流动力学后患者选择保守治疗,19天平安出院。
证据类型、等级与局限
- 证据类型:病例报告。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Left ventricular free wall rupture (LVFWR) is a rare and fatal mechanical complication following an acute myocardial infarction (AMI). Cases of survival after LVFWR due to ST-segment elevation myocardial infarction (STEMI) treated with a conservative treatment strategy are extremely rare. In this case, a 55-year-old male patient with several cardiovascular risk factors presented to the emergency department with symptoms of ongoing chest pain and syncope. The patient's electrocardiogram was in sinus rhythm with ST-elevation on I, aVL, and V4-6 leads. His myoglobin and troponin I levels were elevated. Due to the unstable hemodynamic state of the patient, bedside echocardiography was performed. The echocardiography indicated LVFWR after AMI. Pericardiocentesis was used to restore a satisfactory hemodynamic state in the patient. Following the initial treatment, the patient opted for a conservative treatment strategy and was uneventfully discharged after 19 days.
参考来源
- Yan L, Wang H, Su B, et al. Survival after left ventricular free wall rupture following acute myocardial infarction by conservative treatment. Am J Emerg Med. 2020. PMID: 32829991. doi:10.1016/j.ajem.2020.08.035
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。